Seeking Alpha

Baird defends Regeneron (REGN -2.1%) this morning, saying the drug developer's downstream has...

Baird defends Regeneron (REGN -2.1%) this morning, saying the drug developer's downstream has significant potential. The firm cites the beginning of REGN's Phase lll testing of REGN727 next month, plus FDA guidance that cardiovascular outcomes will not be a prerequisite for approval.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|